STReetlab Assessment Tool of Activities Daily Living in Glaucoma Patient
NCT ID: NCT05747781
Last Updated: 2023-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
100 participants
INTERVENTIONAL
2023-03-01
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The development and validation of new tests could be used to assess the efficacy of innovative treatments for visually impaired patients and/or optimize management strategies.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objective of this project is to validate performance criteria (PerfO) using standardized tasks to assess the quality of life of patients but also to better judge the severity of glaucoma damage. The fidelity, reproducibility, validity and sensitivity of these new tests will be studied. This study will include two phases: a pilot phase to refine the parameters of the tests for the target population, and a validation phase for the tools.
This study will be performed in two phases: pilot phase and validation phase.
Pilot phase (12 months): 12 glaucoma patients (4 stage 1; 4 stage 2 and 4 stage 3), the objective of this phase is to define the optimal parameters of task content, as well as the conditions of luminosity and contrast.
Validation phase: 66 glaucoma patients classified into 3 groups of 22 patients according to the stage of severity (22 stage 1; 22 stage 2 and 22 stage 3) and 22 healthy volunteers matched for age and sex (matching rules ± 5 years).
The objective of this phase is to validate tests that will allow the evaluation of the impact of peripheral visual impairment on the sensory and motor performances of patients in their daily life.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pilot Phase
12 patients with glaumatous optic neuropathy
Pilot Phase: standardized behavioral task
Pilot Phase:
* Mobility under variable light conditions (scotopic, photopic, glare, dark adaptation), performed in a virtual environment.
* Visual search for objects in real life scenes (office, kitchen, living room) performed in a virtual environment.
* Ability to drive (UFOV and DVFAT psychophysical tests).
Validation Phase
66 patients with glaumatous optic neuropathy 12 subjects with no known visual impairment
Validation Phase: standardized behavioral task
Validation Phase:
* Mobility in variable light conditions (photopic and scotopic), performed in real and virtual environments.
* Visual search for objects in real scenes (office, kitchen, bedroom, living room) performed in a virtual environment.
* Driving ability (two psychophysical tests UFOV and DVFAT, one supervised road test).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pilot Phase: standardized behavioral task
Pilot Phase:
* Mobility under variable light conditions (scotopic, photopic, glare, dark adaptation), performed in a virtual environment.
* Visual search for objects in real life scenes (office, kitchen, living room) performed in a virtual environment.
* Ability to drive (UFOV and DVFAT psychophysical tests).
Validation Phase: standardized behavioral task
Validation Phase:
* Mobility in variable light conditions (photopic and scotopic), performed in real and virtual environments.
* Visual search for objects in real scenes (office, kitchen, bedroom, living room) performed in a virtual environment.
* Driving ability (two psychophysical tests UFOV and DVFAT, one supervised road test).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: 18 - 80 years,
* Visual acuity of at least 6/10th binocular,
* Patient followed at Quinze-Vingts and presenting with chronic stable glaucoma defined by the glaucoma ophthalmologist,
* MMSE questionnaire score ≥ 25/30 or ≥ 16/25 (if the patient no longer drives),
* Ability to give consent and comply with the study protocol,
* Person with Social Security coverage.
* Recruitment of glaucoma patients will be based on the criteria defined by the HPA classification (Appendix) on the basis of the Humphrey visual field, for categorization of patients into three stages of optic neuropathy progression (early stage "1", moderate "2" and advanced "3").
* Always drivers in possession of a valid driver's license,
* Driven at least 500 km in the past year.
Healthy volunteer:
* Age: 18 - 80 years.
* Age and sex matching between healthy volunteers and glaucoma patients (± 5 years).
* MMSE questionnaire score ≥ 25/30.
* Visual acuity of at least 10/10th in binocular.
* Ability to give consent and comply with the study protocol.
* Person with a Social Security plan.
* Always drivers in possession of a valid driver's license,
* Driven at least 500 km in the past year.
Exclusion Criteria
* Inability to personally give consent.
* Participants will not have neurodegenerative diseases or any other disease that could interfere with the assessments planned during this study.
* Participants will not have any other ophthalmologic diseases other than glaucoma.
* Drug treatments that may cause motor, visual, or cognitive impairment (PSAs, neuroleptics, etc.) or that may interfere with the study assessments.
* Condition that limits ability to move.
* Inability to read.
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christophe BAUDOUIN, Pr
Role: PRINCIPAL_INVESTIGATOR
Hôpital National de la Vision des15-20
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-A02573-40
Identifier Type: REGISTRY
Identifier Source: secondary_id
P22-05
Identifier Type: -
Identifier Source: org_study_id